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ABSTRACT
Aim: To compare 1-year follow-up results of photore-
fractive keratectomy (PRK) with mitomycin C (MMC) and
laser in situ keratomileusis (LASIK) for custom correction
of myopia.
Methods: Eighty-eight eyes of 44 patients with moderate
myopia were randomised to PRK with 0.002% MMC for
1 min in one eye and LASIK in the fellow eye. The 1-year
follow-up was evaluated.
Results: There were no differences between LASIK and
MMC-PRK eyes preoperatively. Forty-two patients com-
pleted the 1-year follow-up. MMC-PRK eyes achieved
better uncorrected visual acuity (p=0.03) and better
best-spectacle-corrected visual acuity (p,0.001) 1 year
after surgery. SE did not differ in the two groups during
follow-up (p=0.12). Clinically significant haze was not
found in surface ablation eyes. LASIK eyes showed a
greater higher-order aberration (p=0.01) and lower
contrast sensitivity (p,0.05) than MMC-PRK eyes
postoperatively. Excellent vision was reported in 64% of
LASIK and 74% of MMC-PRK eyes 1 year after surgery.
The corneal resistance factor and corneal hysteresis
(ORA, Reichert) were higher in LASIK than in MMC-PRK
eyes (p,0.01) at the last follow-up.
Conclusions: Wavefront-guided PRK with 0.002% MMC
was more effective than wavefront-guided LASIK for
correction of moderate myopia. Further research is
necessary to determine the optimal concentration,
exposure time and long-term corneal side effect of MMC.
Excimer laser photorefractive keratectomy (PRK)
with adjunctive mitomycin C (MMC; MMC–PRK)
has recently been used as an alternative to laser in
situ keratomileusis (LASIK) for surgical correction
of refractive errors.
1–3 Although surface ablation
usually has a slower visual recovery and more early
postoperative discomfort, it avoids LASIK flaps
complications and possibly results in less corneal
biomechanical instability.
45
Mitomycin C is an alkylating agent that inhibits
DNA and RNA replication and protein synthesis.
6
It regulates fibroblast proliferation and differentia-
tion, and subsequently blocks myofibroblast for-
mation, which is responsible for corneal haze after
PRK in high myopic corrections.
78Recent studies
have shown that low-dose MMC (0.002%) has a
similar efficacy to standard MMC concentration
(0.02%) in preventing postoperative haze following
surface ablation for moderate myopia corrections,
and also minimise potential side effects.
791 0
There are not many papers in the literature
comparing MMC-PRK and LASIK. Randleman et
al
3 compared wavefront-optimised PRK with
standard dose MMC and wavefront-optimised
LASIK in 272 preoperative refraction-matched eyes
for moderate myopia corrections. They found a
better uncorrected visual acuity (UCVA) and
spherical equivalent (SE) in MMC-PRK eyes
3 months after surgeries.
The purpose of this study is to compare visual
acuity (VA) outcomes (including satisfaction ques-
tionnaire, aberrometry, contrast sensitivity) and
corneal biomechanical properties 1 year after
wavefront-guided PRK with 0.002% MMC and
LASIK for myopic corrections. As a continuum of
our early postoperative outcomes study,
11 we are
unaware of any randomised prospective study in
the literature comparing 1-year results of PRK with
MMC and LASIK consecutively performed in both
eyes of the same patients at the same treatment
sitting.
PATIENTS AND METHODS
Study design and patient selection
Forty-four patients (88 eyes) with myopic astig-
matism and an estimated ablation depth greater
than 50 mm using the LADARWave 4000 (Alcon
Laboratories, Fort Worth, Texas) platform in both
eyes (OU) were randomised to receive wavefront-
guided PRK with prophylactic application of MMC
0.002% (0.02 mg/ml) in one eye and wavefront-
guided LASIK in the fellow eye. The right eye of
each patient was randomised at the surgical centre
using a coin toss to either one of the procedures;
the other eye automatically received the other
technique. The ablation was calculated with an
optical zone (OZ) of 6.5 mm diameter and transi-
tion zone (TZ) of 1.25 mm.
The inclusion criteria were best-spectacle-cor-
rected visual acuity (BSCVA) of logMAR 0.0
(Snellen 20/20) or better in OU, at least 6 months’
refraction stability, an estimated residual corneal
ultrasound pachymetry greater than 410 mmi nO U
and a complete ophthalmological exam without
associated diseases.
The exclusion criteria included EyeSys 2000
(EyeSys, Houston, Texas) and/or Orbscan II
(Orbtek/Bausch & Lomb, Munich, Germany)
topographic patterns suggestive of ectatic disease
or disease status that could interfere with the
healing process of the cornea, that is, collagen
vascular disease, diabetes. Patients with a history
of severe ocular trauma or previous ocular surgery
were also excluded.
Approval for the study was granted by the
Institutional Review Board of the Federal
University of Sa ˜o Paulo, Brazil, and the study
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of Helsinki. All patients provided informed consent, and the
Clinical Trial Registration was carried out at http://www.
clinicaltrials.gov at code NCT 00365040.
Surgical procedures
After topical anaesthesia, the central 9 mm diameter epithelium
was removed mechanically using a scarificator blade in all PRK
eyes. Custom ablation (OZ 6.5 mm, TZ 1.25 mm) was then
performed with the LADARWave 4000 laser. Following photo-
ablation, 0.002% MMC was applied to the stromal bed for
1 min. The solution was applied by filling the barrel of a
7.0 mm Hoffer marking trephine centred over the pupil. The
MMC was dried after 60 s using a sterile microsponge. The eye
was then copiously irrigated with 30 cm
3 of balanced salt
solution to wash out residual MMC. A bandage contact lens
(New Vues, CIBA, Duluth) was placed at the end of the
procedure.
After topical anaesthesia and corneal marking, the LASIK flap
was cut using a Moria M2 (Moria, Antony, France) micro-
keratome. ‘‘Ring and stop’’ was chosen accordingly to achieve a
9 mm diameter flap. Custom ablation was then performed.
Corneal irrigation and flap repositioning were done following
photoablation.
No offset or laser nomogram adjustment was used in the two
groups. Surgeries were performed by both authors.
All operated eyes received the same postoperative drug
regimen. Tobramycin 0.3% plus dexamethasone 0.1% drops
were given four times daily for 15 days; artificial tears were
given five times daily for at least 3 months. Patients were
instructed to take pain-relief tablets if necessary. The bandage
contact lens in PRK eyes was removed after complete corneal
reepithelialisation.
No enhancements were performed in any eye during
12 months’ follow-up.
Patient assessment
The preoperative visit involved a comprehensive ophthalmolo-
gical examination including UCVA, BSCVA, cycloplegic refrac-
tion, corneal topography, aberrometry, central ultrasound
pachymetry (USP), slit-lamp microscopy and contrast sensitiv-
ity. Follow-up examinations were scheduled at 1, 3, 6 and
12 months after surgery, and involved the same tests and
assessments performed during the preoperative visit.
UCVA and BSCVA were measured using the Early Treatment
Diabetic Retinopathy Study visual acuity chart (ETDRS,
logMAR notation). Cycloplegic refraction and aberrometry
(LADARWave 4000, Alcon Laboratories) were performed
40 min after two drops (5 min apart) of 1% cyclopentolate.
All aberrations were measured to the fifth Zernike order using a
6.5 mm pupil.
At each follow-up, a satisfaction questionnaire was adminis-
tered prior to any other testing. Patients were asked to assess
their vision in each eye as bad, reasonable, good or excellent;
they were also asked to rate ocular pain, far vision difficulty,
near vision difficulty, glare, photophobia, vision fluctuation,
image distortion and foreign-body sensation in each eye. Each
characteristic was grade on a 0 to 3 scale, with 0 indicating an
absence of symptoms and 3 indicating the worst symptom.
Contrast sensitivity (Optec 6500, FACT, Stereo Optical Co,
Chicago) was determined in each eye with the BSCVA at spatial
frequencies of 1.5, 3, 6, 12 and 18 cycles per degree in mesopic
and photopic conditions. The log base 10 contrast sensitivity
values were used to construct a graph for each spatial frequency
tested.
Biomechanical properties of the cornea were determined
using the Ocular Response Analyser (ORA, Reichert, Depew,
New York) at 1-year follow-up. Corneal hysteresis (CH) and
corneal resistance factor (CRF) were measured in both eyes of
patients.
Statistical analysis was done using analysis of variance with
repeated measures (over time and between treatments,
Bonferroni) using the statistics software SPSS 12 (SPSS,
Chicago). The definition of statistical significance was set at
p,0.05.
RESULTS
Forty-four patients (88 eyes) were enrolled in this study. The
mean age in both groups was 31.7 years, range 21 to 54 years
old. There were 26 females (59%) and 18 (41%) males. The
mean UCVA, mean BSCVA and mean SE correction before
surgery were 1.23 (SD 0.15) (logMAR notation), 20.09 (0.07)
(logMAR) and 23.99 (1.20) D, respectively in LASIK eyes and
1.21 (0.15) (logMAR), 20.08 (0.08) (logMAR) and 23.85 (1.12)
D, respectively in surface ablation eyes (p.0.05). The mean
preoperative USP was 542.8 (25) mm in LASIK eyes and 544.7
(25.5) mm in MMC-PRK eyes (p=0.013). The mean higher-
order aberration (HOA) was 0.39 (0.16) mm in LASIK and 0.38
(0.13) mm in MMC-PRK eyes (p.0.05). The mean ablation
depth (AD) was 73.09 (14.55) mm in LASIK eyes and 70.7
(14.07) mm in MMC-PRK eyes (p=0.074). There was also no
statistically significant between-group difference in contrast
sensitivity before surgery (p.0.05). Forty-two patients com-
pleted 1-year follow-up.
The UCVA in the two groups during follow-up is summarised
in fig 1. The MMC-PRK group achieved statistically significant
better mean values 3, 6 and 12 months after surgery. The mean
BSCVA results in the two groups are shown in fig 2. MMC-PRK
eyes had statistically significant better results at the 1-year
follow-up. There was no statistically significant difference in
mean SE in the two groups during 1-year follow-up (p=0.116).
At the last follow-up, the mean SE was 0.45 (0.54) D in LASIK
and 0.48 (0.38) D in MMC-PRK eyes.
Figure 1 Uncorrected visual acuity (UCVA, logMAR notation, mean and
SD) in laser in situ keratomileusis (LASIK) and photorefractive
keratectomy with mitomycin C (MMC-PRK) eyes during 1-year follow-up.
A UCVA of 20.2 or better (Snellen 20/12.5) was achieved in 52% of eyes
after MMC-PRK compared with 31% of eyes after LASIK at the last visit
(p=0.027). *Statistically significant results.
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(more than grade 1 haze with the Fantes
12 scale during follow-
up).
The total root-mean-square (RMS), defocus, astigmatism,
HOA and spherical aberration were statistically significantly
higher in LASIK eyes than in the MMC-PRK group during the 1-
year follow-up (p,0.05). Other higher-order aberrations, up to
fifth-order aberrations excluding coma and spherical aberration,
were also higher in the LASIK group 3, 6 and 12 months after
surgery (p,0.01). HOA, coma (Z 3) and spherical aberration (Z
4,0) showed a statistically significant increase in both groups
postoperatively. Table 1 lists the magnitude of wavefront
aberrations until the fifth order for a 6.5-mm pupil in both
groups at 12 months’ follow-up.
Figure 3 shows the contrast sensitivity in photopic and
mesopic conditions in the two groups 1 year after surgery.
MMC-PRK eyes presented statistically significant better meso-
pic contrast sensitivity at spatial frequencies 3, 6 and 18 cpd
during the 1-year follow-up. Surface ablation eyes also showed a
statistically significant better photopic contrast sensitivity than
LASIK eyes at spatial frequencies of 6, 12 and 18 cpd post-
operatively.
One year after surgery, excellent vision was reported in 64%
and 74% of LASIK and MMC-PRK eyes respectively. Far-vision
difficulty, glare and vision fluctuation were also more fre-
quently reported in LASIK than in MMC-PRK eyes at last
follow-up. Foreign-body sensation was more prevalent in
MMC-PRK eyes 1 year after surgery.
Corneal resistance factor (CRF) and corneal hysteresis (CH)
were statistically significantly higher in the LASIK group than
in MMC-PRK eyes 1 year after surgery (p,0.01, table 2). The
central ultrasound pachymetry was statistically significant
lower in PRK with MMC eyes in all postoperative examina-
tions.
DISCUSSION
Recently, there has been renewed interest in advanced surface
ablation which includes PRK with MMC, laser subepithelial
keratectomy and epi-LASIK. Although associated with a longer
visual rehabilitation period, surface ablation techniques are less
related to initial or secondary flap complications, including
ectasia.
5
PRK for correcting intermediate to high levels of myopia may
result in a strong wound-healing reaction, leading to haze
formation and suboptimal refractive outcomes. We chose to use
intraoperative topical application of MMC in a millesimal
concentration (0.002%) during PRK based on Netto et al’s
study.
7 These lower concentrations of MMC have a similar
efficacy to higher concentrations in reducing haze, but also
minimise potential side effects. Thornton et al
91 0reported two
studies with surface ablation and low-dose mitomycin C. In the
first study,
9 they found that low-dose MMC (0.002%) after laser
epithelial keratomileusis (LASEK) for correction of moderate
and high myopia results in less corneal haze than in eyes not
receiving this agent. In the second study,
10 the authors retro-
spectively compared the lower dose MMC with that of the
standard dose (0.02%) in eyes treated with PRK for myopia.
They found that MMC 0.02% is more effective than low-dose
MMC in preventing postoperative haze following surface
ablation for myopia greater than 26.00 D and an ablation
depth greater than 75 mm. However, for moderate myopia and
shallow depth, the authors found both MMC concentrations to
be equally effective. The concern for mitomycin C use stems
from complications arising in scleral and corneoscleral proce-
dures with mitomycin C, including peripheral keratolysis and
scleral melting.
13 Although these effects have not been shown to
occur in cases of topical MMC use during surface refractive
surgery, some concern still exists for MMC long-term toxicity
to keratocytes, endothelial cells, and intraocular structures.
78
Some studies have reported a decrease in endothelial cell count
and detection of MMC in the anterior chamber in eyes that had
received MMC after surface laser ablation.
14–16
This study suggests a potential advantage for surface ablation
over LASIK at the 1-year follow-up. At 12 months post-
operatively, UCVA and BSCVA were better in MMC-PRK eyes.
More eyes achieved the supranormal UCVA of 20.2 or better in
MMC-PRK (52%) than in LASIK (31%) eyes at the 1-year
follow-up. Seventy-four per cent of MMC-PRK and 43% of
LASIK eyes gained one or more BSCVA lines at 12 months
postoperatively. There were no differences in SE at last follow-
up, and both groups presented a mean hyperopic shift around
Figure 2 Best spectacle-corrected visual acuity (BSCVA, logMAR
notation, mean and SD) in laser in situ keratomileusis (LASIK) and in
photorefractive keratectomy with mitomycin C (MMC-PRK) eyes during
the 1-year follow-up. At 1 year postoperatively, significantly more eyes
in the surface ablation group gained one or more lines (74% in MMC-PRK
eyes vs 43% in LASIK eyes, p,0.001).
Table 1 Wavefront analysis using a 6.5 mm pupil diameter (mean and SD) in laser in situ keratomileusis
(LASIK) and in fellow photorefractive keratectomy with mitomycin C (MMC-PRK) eyes 1 year after surgery
Total RMS* Defocus* Astigmatism* HOA* Coma Spherical* Other*
LASIK 1.15 (0.37) 0.75 (0.45) 0.36 (0.29) 0.66 (0.19) 0.32 (0.17) 0.43 (0.20) 0.33 (0.13)
MMC-PRK 0.91 (0.30) 0.57 (0.35) 0.25 (0.18) 0.58 (0.24) 0.29 (0.20) 0.39 (0.21) 0.26 (0.12)
HOA, higher-order aberrations until the fifth order; Other, higher-order aberrations until the fifth-order RMS other than coma and
spherical aberration; RMS, root mean square; Spherical, spherical aberration.
*Statistically significant differences between groups. Forty-two patients completed follow-up.
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appeared more precise (lower SDs in MMC-PRK eyes), and
more eyes were myopic after LASIK surgery and hyperopic after
MMC-PRK. Nomogram adjustments should improve refractive
outcomes in both groups and might reduce the UCVA
advantage of MMC-PRK. Our findings are similar to those of
Randleman et al.
3 In a retrospective study comparing 272
refraction-matched eyes that had undergone MMC-PRK or
LASIK, they found significantly better results in surface-
ablation eyes 3 months after wavefront-optimised surgeries.
In our study, we found better aberration outcomes in MMC-
PRK eyes. Total RMS, HOA, defocus, astigmatism, spherical
aberration and other aberrations were lower in eyes that had
received MMC-PRK surgery. We conjecture that the absence of
a flap interface and the modulation of corneal wound healing
with MMC resulted in less induction of aberrations. It is unclear
whether the decreases in aberrations are clinically relevant, but
MMC-PRK eyes had better refractive outcomes, had better
contrast sensitivity scores and were better rated in terms of
visual satisfaction. Porter et al
17 reported a significant increase in
higher-order aberrations of approximately 30% 2 months after
cutting a Hansatome (Bausch & Lomb, Rochester, New York)
microkeratome LASIK flap without laser application. Pallikaris
et al
18 also found a significant increase in total higher-order
wavefront aberrations following flap formation. Some studies
have demonstrated that femtosecond laser flap formation
results in a smaller increase in higher-order aberrations than
mechanical flap creation.
19
Several authors have reported significant correlations
between increased higher-order aberrations and decreased
contrast sensitivity, especially total HOA, coma and spherical
aberrations.
20 21 Other authors have reported the correlation
between visual symptoms and ocular aberrations, such as
monocular diplopia with coma, and starburst and glare with
spherical aberration.
21 22 In the present study, MMC-PRK eyes
had lower aberrations and better mesopic and photopic contrast
sensitivity scores than LASIK eyes. Surface ablation eyes scored
higher in terms of the visual-satisfaction questionnaire.
Corneal hysteresis and corneal resistance factor are biome-
chanical properties of the cornea which reflect its viscoelastic
properties. Corneal hysteresis has been previously shown to
decrease following LASIK surgery.
23 Corneal hysteresis and
corneal resistance factor values also have been shown to be
significantly decreased in keratoconic eyes.
23 24 We found a
statistically significant difference in corneal hysteresis and
corneal resistance factor between LASIK and MMC-PRK eyes
1 year after surgeries. In our study, eyes that had received MMC
during PRK showed a lower CH and CRF than LASIK eyes. One
weakness of our study is that we did not measure preoperative
corneal hysteresis and corneal resistance factor in both groups.
Kirwan and O’Keefe
25 found a statistically significant decrease
in hysteresis 3 months after LASIK and LASEK with similar
decrements in both treatments groups. The authors also found a
moderately strong correlation between central corneal thickness
(CCT) and hysteresis. In our study, MMC-PRK eyes had
statistically significant thinner corneal measures than LASIK
eyes 1 year after surgeries. We are not sure whether the lower
hysteresis values found in MMC-PRK eyes are related to
reduced biomechanical integrity of the cornea or are a result
of the lower postoperative CCT found in PRK with MMC eyes.
Future studies are needed to determine the Ocular Response
Analyser accuracy to measure the biomechanical properties of
the cornea and its clinical relevance.
In the current study, wavefront-guided PRK with 0.002%
MMC was more effective than wavefront-guided LASIK for
correction of moderate myopia during the 1-year follow-up.
Surface ablation eyes presented a better UCVA, BSCVA,
aberrometry and contrast sensitivity, and were better rated in
a subjective questionnaire than LASIK eyes. However, before
widespread use of prophylactic 0.002% MMC can be imple-
mented, further research is necessary to determine the optimal
concentration and exposure time, and the long-term corneal
side effect of mitomycin C exposure.
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